A batch of tuberculosis medication used across Botswana has been found to be substandard, prompting the government to re-assess dozens of patients after surveillance data showed an unusual spike in treatment failures, health authorities announced last week.
In a public notice dated December 4, the Ministry of Health (MoH) said laboratory tests revealed that a Fixed Dose Combination (FDC) drug used in TB treatment was “deficient of two critical anti-TB molecules: Rifampicin and Ethambutol” – both key to suppressing the disease. The finding followed a review of national treatment patterns that showed an unexpected rise in poor outcomes across several districts.
There's more to this story
But to keep reading, we need you to subscribe.
Investigative journalism is an indispensable part of a healthy society, but it's also expensive to produce. We are reliant on subscriptions to fund our work, and while you can enjoy most of our stories for free, a small number of premium features are reserved for subscribers.
You can subscribe for one week, a month or a full year - the choice is yours.
Save 77% on an annual subscription. Click here to find out how.
Existing subscribers can log in to keep reading here.
